A Food Effect Study of Apatinib Mesylate in Healthy Subjects

NCT ID: NCT04341090

Last Updated: 2021-10-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 42 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-05-13
• Study Completion Date: 2020-07-06

Brief Summary

The primary objective of the study was to assess the effect of high-fat and low-fat meal on the pharmacokinetics of apatinib mesylate in Chinese adult healthy subjects.

The secondary objective of the study was to assess the safety of apatinib mesylate administered in adult healthy subjects.

Conditions

Healthy Subjects

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Arm 1

Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after fasted, the second dose will be after low-fat meal, the third dose will be after high-fat meal

Group Type: EXPERIMENTAL

Apatinib Mesylate

Intervention Type: DRUG

Single dose of apatinib mesylate after high-fat meal, low fat meal and fast

Arm 2

Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after high-fat meal, the second dose will be after fasted, the third dose will be after low-fat meal

Group Type: EXPERIMENTAL

Apatinib Mesylate

Intervention Type: DRUG

Single dose of apatinib mesylate after high-fat meal, low fat meal and fast

Arm 3

Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after low-fat meal, the second dose will be after high-fat meal, the third dose will be after fasted

Group Type: EXPERIMENTAL

Apatinib Mesylate

Intervention Type: DRUG

Single dose of apatinib mesylate after high-fat meal, low fat meal and fast

Arm 4

Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after fasted, the second dose will be after high-fat meal, the third dose will be after low-fat meal

Group Type: EXPERIMENTAL

Apatinib Mesylate

Intervention Type: DRUG

Single dose of apatinib mesylate after high-fat meal, low fat meal and fast

Arm 5

Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after low-fat meal, the second dose will be after fasted, the third dose will be after high-fat meal

Group Type: EXPERIMENTAL

Apatinib Mesylate

Intervention Type: DRUG

Single dose of apatinib mesylate after high-fat meal, low fat meal and fast

Arm 6

Drug:apatinib mesylate tablet , 250 mg, 3 discrete single doses separated by 4-days: the first dose will be after high-fat meal, the second dose will be after low-fat meal, the third dose will be after fasted

Group Type: EXPERIMENTAL

Apatinib Mesylate

Intervention Type: DRUG

Single dose of apatinib mesylate after high-fat meal, low fat meal and fast

Interventions

Apatinib Mesylate

Single dose of apatinib mesylate after high-fat meal, low fat meal and fast

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. 18-45 years of age, male or female, each gender should be more than 1/4 of the whole sample size.

2. The weight of male subject ≥50kg, weight of female subject ≥45kg, 19≤BMI≤28kg/m2

3. In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG;

4. Agree to take approved method of contraception during the clinical trail and 8 weeks after the last dose of apatinib. Female subject should be negative in the pregnancy test;

5. Able to comprehend and willing to sign an informed consent form (ICF)

Exclusion Criteria

1. History of drug allergy, or allergic to apatinib or ingredients;

2. Drinking 14 units of alcohol per week within 6 months prior dosing(1 unit = 360 mL of beer, or 150mL of wine) ;

3. Take any prescription or traditional Chinese medicines within four weeks prior dosing; take any over-the-counter medication, vitamin products within two weeks before dosing;

4. Take any clinical trial drugs within 3 months prior dosing;

5. Participate in blood donation within 3 months before screening and donate blood volume ≥400mL or blood loss ≥400mL, or receive blood transfusion; or donate blood volume≥200mL or blood loss ≥200mL within 1 month prior dosing.

6. Combined with other viral infections (anti-HCV, anti-HIV positive, HBsAg positive) or combined with syphilis infection;

7. Anyone who refuse to stop ingest foods or drinks containing caffeine, xanthine or alcohol from 48 hours before dosing to the end of the study;

8. Anyone who refuse to stop ingesting grapefruit or grapefruit-containing products from 7 days before dosing to the end of the study;

9. The investigator believes that the subjects are not eligible to participate in this trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Beijing Luhe Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Countries

China

Other Identifiers

HR-APTN-I-009

Identifier Type: -

Identifier Source: org_study_id